Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Neurelis, Inc.
Keeping Track: Disappointment For Mesoblast And Aquestive; Opdivo/Yervoy Add Mesothelioma Claim; Pediatric Approvals
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
The latest drug development news and highlights from our US FDA Performance Tracker.
The pipeline for new drug candidates remains healthy as 2019 begins, with almost 40 novel agents already under FDA review. But the chances of another record-breaking year are threatened by a confluence of safety issues that are putting risk management back in the spotlight – and by the widening ripple effects of the recent US government shutdown.
The latest drug development news and highlights from our FDA Performance Tracker.
- Specialty Pharmaceuticals
- Large Molecule
- Other Names / Subsidiaries
- Aegis Therapeutics